MarketCap
Facebook
X
TelegramFluidigm Corporation General and Administrative Expenses 2011-2026 | FLDM
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Fluidigm Corporation
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 97.9 M | 84.5 M | 79.8 M | 79.5 M | 93.2 M | 83 M | 71.3 M | 48.4 M | 38.5 M | 31.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 97.9 M | 31.3 M | 70.7 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K |  USA |
 |
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B | USA |
 |
Fulgent Genetics
FLGT
|
117 M | $ 19.5 | 7.5 % | $ 600 M | USA |
 |
Celcuity
CELC
|
27.2 M | $ 92.47 | 3.96 % | $ 4.32 B | USA |
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
9.06 M | $ 5.76 | 11.41 % | $ 7.66 M | USA |
 |
Guardant Health
GH
|
211 M | $ 133.06 | 4.75 % | $ 16.7 B | USA |
 |
Castle Biosciences
CSTL
|
229 M | $ 21.6 | 5.93 % | $ 626 M | USA |
 |
Aspira Women's Health
AWH
|
7.96 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
21.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M |  Britain |
 |
CareDx, Inc
CDNA
|
108 M | $ 23.12 | 3.63 % | $ 1.23 B | USA |
 |
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
ICON Public Limited Company
ICLR
|
780 M | $ 152.8 | 6.18 % | $ 12 B |  Irlanda |
 |
Check-Cap Ltd.
CHEK
|
2.37 M | - | - | $ 9.42 M |  Israel |
 |
Interpace Biosciences
IDXG
|
9.48 M | $ 1.79 | 2.29 % | $ 7.92 M | USA |
 |
Illumina
ILMN
|
1.09 B | $ 168.06 | -1.68 % | $ 26 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
15.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
4.16 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
Lantheus Holdings
LNTH
|
275 M | $ 102.82 | 2.56 % | $ 6.94 B | USA |
 |
Charles River Laboratories International
CRL
|
743 M | $ 185.79 | 3.29 % | $ 9.21 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | USA |
 |
Mettler-Toledo International
MTD
|
998 M | $ 1 180.48 | 0.95 % | $ 24.3 B |  Schweiz |
 |
Medpace Holdings
MEDP
|
198 M | $ 458.69 | 1.75 % | $ 13.2 B | USA |
 |
NeoGenomics
NEO
|
273 M | $ 11.31 | 11.54 % | $ 1.45 B | USA |
 |
Exact Sciences Corporation
EXAS
|
889 M | - | - | $ 19.8 B | USA |
 |
Natera
NTRA
|
1.18 B | $ 222.1 | 4.84 % | $ 30.4 B | USA |
 |
National Research Corporation
NRC
|
54.8 M | $ 19.75 | 3.73 % | $ 442 M | USA |
 |
Myriad Genetics
MYGN
|
257 M | $ 4.69 | 6.59 % | $ 434 M | USA |
 |
Personalis
PSNL
|
53.6 M | $ 12.1 | 12.24 % | $ 1.08 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
628 M | $ 25.99 | 2.48 % | $ 24.6 B |  Niderland |
 |
Senseonics Holdings
SENS
|
52.5 M | $ 7.01 | 4.32 % | $ 293 M | USA |
 |
QIAGEN N.V.
QGEN
|
128 M | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
132 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
2.98 M | $ 2.15 | 1.9 % | $ 4.94 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
2.22 B | $ 260.97 | 0.79 % | $ 21.7 B | USA |
 |
Twist Bioscience Corporation
TWST
|
247 M | $ 73.93 | 2.21 % | $ 4.42 B | USA |
 |
Thermo Fisher Scientific
TMO
|
8.73 B | $ 482.03 | 1.7 % | $ 182 B | USA |
 |
Trinity Biotech plc
TRIB
|
28.8 M | $ 0.68 | -2.4 % | $ 244 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
218 M | $ 9.12 | 3.52 % | $ 1.98 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.97 B | $ 196.12 | 1.27 % | $ 21.8 B | USA |
 |
Invitae Corporation
NVTA
|
192 M | - | - | $ 21.2 M | USA |
 |
Waters Corporation
WAT
|
240 M | $ 376.47 | -0.87 % | $ 22.4 B | USA |